SG11201707606RA - Designed ankyrin repeat domains with binding specificity for serum albumin - Google Patents
Designed ankyrin repeat domains with binding specificity for serum albuminInfo
- Publication number
- SG11201707606RA SG11201707606RA SG11201707606RA SG11201707606RA SG11201707606RA SG 11201707606R A SG11201707606R A SG 11201707606RA SG 11201707606R A SG11201707606R A SG 11201707606RA SG 11201707606R A SG11201707606R A SG 11201707606RA SG 11201707606R A SG11201707606R A SG 11201707606RA
- Authority
- SG
- Singapore
- Prior art keywords
- serum albumin
- binding specificity
- ankyrin repeat
- repeat domains
- designed ankyrin
- Prior art date
Links
- 102000008102 Ankyrins Human genes 0.000 title 1
- 108010049777 Ankyrins Proteins 0.000 title 1
- 102000007562 Serum Albumin Human genes 0.000 title 1
- 108010071390 Serum Albumin Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15162502 | 2015-04-02 | ||
| EP15162511 | 2015-04-02 | ||
| PCT/EP2016/057272 WO2016156596A1 (fr) | 2015-04-02 | 2016-04-01 | Domaines de répétition d'ankyrine artificiels ayant une spécificité de liaison pour l'albumine sérique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707606RA true SG11201707606RA (en) | 2017-10-30 |
Family
ID=55650423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707606RA SG11201707606RA (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9458211B1 (fr) |
| EP (2) | EP3277711B9 (fr) |
| JP (1) | JP6552636B2 (fr) |
| KR (2) | KR102427117B1 (fr) |
| CN (1) | CN107454904A (fr) |
| AU (3) | AU2016240220B2 (fr) |
| BR (1) | BR112017020986A2 (fr) |
| CA (1) | CA2979602C (fr) |
| CL (1) | CL2017002454A1 (fr) |
| CO (1) | CO2017009954A2 (fr) |
| ES (1) | ES2953482T3 (fr) |
| HK (1) | HK1244009A1 (fr) |
| IL (2) | IL276944B (fr) |
| MX (2) | MX2017012485A (fr) |
| MY (1) | MY179505A (fr) |
| NZ (1) | NZ735803A (fr) |
| PH (1) | PH12017501792A1 (fr) |
| RU (1) | RU2769470C2 (fr) |
| SA (1) | SA517390092B1 (fr) |
| SG (1) | SG11201707606RA (fr) |
| WO (1) | WO2016156596A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
| PL2643349T3 (pl) * | 2010-11-26 | 2020-03-31 | Molecular Partners Ag | Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy |
| SG11201900464TA (en) | 2016-07-20 | 2019-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| MX2019003298A (es) * | 2016-09-22 | 2019-09-26 | Molecular Partners Ag | Proteinas de union recombinantes y sus usos. |
| WO2019011167A1 (fr) * | 2017-07-12 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | Protéine recombinante bispécifique |
| SG11202001420VA (en) * | 2017-08-18 | 2020-03-30 | Cambridge Entpr Ltd | Modular binding proteins |
| EP3856245A4 (fr) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | ANTICORPS MULTISPÉCIFIQUES CIBLANT HPTP- ß (VE-PTP) ET VEGF |
| WO2020198074A1 (fr) * | 2019-03-22 | 2020-10-01 | Reflexion Pharmaceuticals, Inc. | Composés d-peptidiques pour facteur de croissance endothélial vasculaire (vegf) |
| MX2021014649A (es) | 2019-06-04 | 2022-01-06 | Molecular Partners Ag | Dominio de repetición de anquirina diseñado con estabilidad mejorada. |
| US20220242973A1 (en) * | 2019-06-04 | 2022-08-04 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| EP3980452A1 (fr) | 2019-06-04 | 2022-04-13 | Molecular Partners AG | Protéines de liaison à 4-1bb recombinées et leur utilisation |
| TW202112804A (zh) | 2019-06-04 | 2021-04-01 | 瑞士商分子夥伴股份有限公司 | 多特異性蛋白質 |
| KR20220113492A (ko) | 2019-12-11 | 2022-08-12 | 몰리큘라 파트너스 아게 | 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인 |
| CA3161319A1 (fr) | 2019-12-11 | 2021-06-17 | Victor LEVITSKY | Proteines de liaison de complexe peptide-mhc de recombinaison, leur production et leur utilisation |
| MX2022013945A (es) * | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| MX2022014326A (es) | 2020-05-14 | 2023-02-09 | Molecular Partners Ag | Proteinas multiespecificas. |
| JP2023528207A (ja) | 2020-05-14 | 2023-07-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えｃｄ４０結合タンパク質及びそれらの使用 |
| EP3957649A1 (fr) | 2020-08-18 | 2022-02-23 | Athebio AG | Modules de coiffage de domaines de répétition d'ankyrine à n-terminaux améliorés |
| JP2023554379A (ja) * | 2020-12-16 | 2023-12-27 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換えｃｄ３結合タンパク質及びそれらの使用 |
| JP2023554351A (ja) | 2020-12-16 | 2023-12-27 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規の徐放性プロドラッグ |
| EP4305063A1 (fr) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Promédicaments clivables par protéase |
| US20240150475A1 (en) | 2021-03-09 | 2024-05-09 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| BR112023018293A2 (pt) | 2021-03-09 | 2023-10-31 | Molecular Partners Ag | Acopladores de célula t multiespecíficos à base de darpin |
| EP4304730A1 (fr) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Nouveaux engageurs de cd33 à base de darpin |
| WO2023110983A1 (fr) | 2021-12-14 | 2023-06-22 | Molecular Partners Ag | Domaines de répétition modélisés à double spécificité de liaison et leur utilisation |
| CN114957426B (zh) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | Sp6rars及其在防治蜚蠊目昆虫中的应用 |
| WO2024028278A1 (fr) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Domaines de répétition conçus à charges modifiées et leur utilisation |
| WO2024038307A1 (fr) | 2022-08-19 | 2024-02-22 | Novartis Ag | Schémas posologiques pour molécules de liaison au sars-cov-2 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| EP1332209B1 (fr) | 2000-09-08 | 2009-11-11 | Universität Zürich | Groupes de proteines a domaines de repetition comprenant des modules de repetition |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| NZ591733A (en) | 2004-11-12 | 2012-10-26 | Bayer Schering Pharma Ag | Recombinant newcastle disease virus comprising a transgene encoding a fusion protein comprising a binding domain and a heterologous domain comprising an enzyme |
| MX2007014359A (es) | 2005-05-18 | 2008-02-06 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| NZ564695A (en) | 2005-07-08 | 2009-02-28 | Univ Zuerich | Phage display using cotranslational translocation of fusion polypeptides |
| EP1996937A4 (fr) | 2006-03-06 | 2009-04-08 | Amunix Inc | Materiels génétiques et utilisations correspondantes |
| DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
| JP2010539915A (ja) | 2007-09-24 | 2010-12-24 | ユニバーシティ・オブ・チューリッヒ | 設計されたアルマジロリピートタンパク質 |
| ES2836948T3 (es) * | 2008-11-03 | 2021-06-28 | Molecular Partners Ag | Proteínas de unión que inhiben la interacción del receptor de VEGF-A |
| AU2011212442A1 (en) | 2010-02-05 | 2012-08-09 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質 |
| PL2933262T3 (pl) * | 2010-07-09 | 2018-10-31 | Affibody Ab | Polipeptydy |
| BR112013001431A2 (pt) * | 2010-07-19 | 2016-05-31 | Hoffmann La Roche | método de identificação de pacientes com maior probabilidade de reação a terapia anticâncer |
| CN103459422A (zh) * | 2010-11-24 | 2013-12-18 | 葛兰素集团有限公司 | 靶向hgf的多特异性抗原结合蛋白 |
| PL2643349T3 (pl) * | 2010-11-26 | 2020-03-31 | Molecular Partners Ag | Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy |
| US8722618B2 (en) | 2011-04-29 | 2014-05-13 | Janssen Biotech, Inc. | IL4/IL13 binding repeat proteins and uses |
| EP2867360B1 (fr) | 2012-06-28 | 2019-05-08 | Molecular Partners AG | Liaison de protéines de répétition ankyrine sur mesure au facteur de croissance dérivé des plaquettes (pdgf) |
| EP2738180A1 (fr) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Protéines de liaison comportant au moins deux domaines de liaison ciblant HER2 |
| US11453708B2 (en) * | 2013-05-31 | 2022-09-27 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
-
2016
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/ko active IP Right Grant
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/fr active Active
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en active Active
- 2016-04-01 MX MX2017012485A patent/MX2017012485A/es unknown
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/ko not_active Application Discontinuation
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/fr active Pending
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/es unknown
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/zh active Pending
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/pt active Search and Examination
- 2016-04-01 CA CA2979602A patent/CA2979602C/fr active Active
- 2016-04-01 ES ES16713904T patent/ES2953482T3/es active Active
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/ru active
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/ja active Active
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en unknown
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/fr active Application Filing
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 PH PH12017501792A patent/PH12017501792A1/en unknown
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/es unknown
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/es unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/ar unknown
-
2018
- 2018-03-12 HK HK18103392.8A patent/HK1244009A1/zh unknown
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276944A (en) | Designed regions containing ankyrin repeats with specific binding to serum albumin | |
| IL263102A (en) | A serum albumin-binding protein with a single site | |
| IL267894A (en) | Improved serum albumin binding agents | |
| HK1251650A1 (zh) | 用於確定同時結合的基於細胞的fret測定法 | |
| ZA201804317B (en) | Altered april binding antibodies | |
| IL267897A (en) | Improved serum albumin binding agents | |
| DK3374392T3 (da) | Forbedrede serumalbuminbindende variable immunglobulindomæner | |
| HK1250737A1 (zh) | 結合cd79的抗體分子 | |
| ZA201701912B (en) | Antigen binding proteins that bind cxcr5 | |
| HK1231497A1 (zh) | 表現不同結合特徵的 抗原結合蛋白 | |
| DK3166970T3 (da) | FORBEDREDE Aß-PROTOFIBRILBINDENDE ANTISTOFFER | |
| IL256298A (en) | Multi-specific binding proteins | |
| ZA201701941B (en) | Antigen binding proteins that bind cxcr3 | |
| IL267318A (en) | link test | |
| ZA201901862B (en) | Modified factor h binding protein | |
| HK1255409A1 (zh) | 結合不動桿菌的抗體結合劑及其用途 | |
| GB201614627D0 (en) | Antigen binding proteins | |
| GB201615588D0 (en) | TSLP Binding Proteins | |
| HUP1600456A2 (en) | Novel cell-based tnf-alpha binding assay | |
| IL235702A0 (en) | Materials and methods for binding myelin binding proteins |